Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | MMP9 | P14780 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 13/20 | 0.33 |
| ▸ | CA2 | P00918 | 13/20 | 0.33 |
| ▸ | CA9 | Q16790 | 12/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA3 | P07451 | 2/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | CA6 | P23280 | 2/20 | 0.32 |
| ▸ | CA5A | P35218 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12723465 | 0.91 | TSHR (0.65) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL17943002 | 0.91 | TSHR (0.65) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL13030889 | 0.85 | — | — | |
| Improsulfan SCHEMBL8954 | 0.83 | USP2 (0.67) | USP2TSHRKDM4EALDH1A1LMNA | |
| Improsulfan SCHEMBL10628525 | 0.81 | USP2 (0.64) | USP2TSHRKDM4EALDH1A1LMNA | |
| Improsulfan SCHEMBL5886799 | 0.81 | TSHR (0.71) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL27700119 | 0.81 | TSHR (0.64) | USP2TSHRKDM4EALDH1A1LMNA | |
| Improsulfan SCHEMBL844581 | 0.81 | USP2 (0.64) | USP2TSHRKDM4EALDH1A1LMNA | |
| Improsulfan SCHEMBL27654142 | 0.79 | TSHR (0.61) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL4472128 | 0.79 | ALDH1A1 (0.61) | USP2TSHRKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9993568-B2 | Compounds comprising self-immolative group | LEGOCHEM BIOSCIENCES, INC. (KR) | 2018-06-12 | — | — | US | disclosed |
| US-9919057-B2 | Compounds comprising self-immolative group | LEGOCHEM BIOSCIENCES, INC. (KR) | 2018-03-20 | — | — | US | disclosed |
| US-20180021451-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | LIGACHEM BIOSCIENCES INC. (KR) | 2018-01-25 | — | — | US | disclosed |
| US-9669107-B2 | Antibody-active agent conjugates and methods of use | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-06 | — | — | US | disclosed |
| US-20170095576-A1 | COMPOUNDS COMPRISING SELF-IMMOLATIVE GROUP | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-04-06 | — | — | US | disclosed |
| US-20170088621-A1 | COMPOSITIONS AND METHODS RELATED TO ANTI-EGFR ANTIBODY DRUG CONJUGATES | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-03-30 | — | — | US | disclosed |
| US-20170088614-A1 | COMPOSITIONS AND METHODS RELATED TO ANTI-CD19 ANTIBODY DRUG CONJUGATES | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-03-30 | — | — | US | disclosed |
| US-20160184451-A1 | COMPOUNDS COMPRISING SELF-IMMOLATIVE GROUP | LIGACHEM BIOSCIENCES INC. (KR) | 2016-06-30 | — | — | US | disclosed |
| US-20150105541-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | LIGACHEM BIOSCIENCES INC. (KR) | 2015-04-16 | — | — | US | disclosed |
| US-20140187756-A1 | Methods of preparing antibody-active agent conjugates | LEGOCHEM BIOSCIENCES, INC. (KR) | 2014-07-03 | — | — | US | disclosed |
| US-20140161829-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | LEGOCHEM BIOSCIENCES, INC. (KR) | 2014-06-12 | — | — | US | disclosed |
| US-20120308584-A1 | PROTEIN-ACTIVE AGENT CONJUGATES AND METHOD FOR PREPARING THE SAME | LEGOCHEM BIOSCIENCES, INC. (KR) | 2012-12-06 | — | — | US | disclosed |
| WO-2011141703-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | PROTIVA BIOTHERAPEUTICS INC. (CA) | 2011-11-17 | — | — | WO | disclosed |
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | CAPRARO HANS-GEORG | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105541-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | FCGRT, CD47, FNTA | USP2 2444/4885TSHR 3065/4885KDM4E 3469/4885 |
| US-20170088621-A1 | COMPOSITIONS AND METHODS RELATED TO ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | USP2 1659/4885TSHR 507/4885KDM4E 861/4885 |
| US-20160184451-A1 | COMPOUNDS COMPRISING SELF-IMMOLATIVE GROUP | IAPP, IDE, DNPEP | USP2 2648/4885TSHR 2007/4885KDM4E 4843/4885 |
| US-20170088614-A1 | COMPOSITIONS AND METHODS RELATED TO ANTI-CD19 ANTIBODY DRUG CONJUGATES | CD47, CD22, BCL6 | USP2 2440/4885TSHR 2349/4885KDM4E 195/4885 |
| US-20170095576-A1 | COMPOUNDS COMPRISING SELF-IMMOLATIVE GROUP | IAPP, IDE, DNPEP | USP2 2396/4885TSHR 2134/4885KDM4E 4873/4885 |
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | PI4KA, PIP5K1B, PIP4K2A | USP2 3112/4885TSHR 3280/4885KDM4E 2784/4885 |
| US-20140161829-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | FNTA, FCGRT, CD47 | USP2 2593/4885TSHR 3204/4885KDM4E 3281/4885 |
| US-20180021451-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | FCGRT, CD47, FNTA | USP2 2444/4885TSHR 3065/4885KDM4E 3469/4885 |
| US-20140187756-A1 | Methods of preparing antibody-active agent conjugates | FNTA, GGT1, ICMT | USP2 2236/4885TSHR 3117/4885KDM4E 3216/4885 |
| US-20120308584-A1 | PROTEIN-ACTIVE AGENT CONJUGATES AND METHOD FOR PREPARING THE SAME | FNTA, DNPEP, RCE1 | USP2 1108/4885TSHR 4035/4885KDM4E 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.